| Alzheimer’s disease (mild to moderate dementia) |
| Severe Alzheimer’s dementia (symptomatic treatment) |
| Cognitive decline associated with neurodegenerative disorders |
Tablet
This fixed-dose combination is indicated for the treatment of moderate to severe Alzheimer's disease. Memantine acts as an NMDA receptor antagonist, reducing excitotoxicity, while Donepezil is a cholinesterase inhibitor that enhances acetylcholine levels in the brain.
| Speciality | Neurology | Psychiatry | Geriatric Medicine |
|---|---|
| Tags | Alzheimer’s | Dementia | Cognitive Function | Neuroprotection |
| Strength |
|
| Packing Size |
|
All product details on this website are for reference and informational purposes only and
are not directed at patients or consumers.
As a contract manufacturer,
DM Pharma Pvt Ltd is not responsible for the marketing or end use of these products and disclaims all
liability arising from reliance on this information.
Please consult a healthcare professional before
using any medicinal product.